Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
247.72(c) 245.08(c) 244.68(c) 244.25(c) 242.46(c) Last
1 747 301 1 518 535 2 166 652 1 649 082 1 496 011 Volume
+1.22% -1.07% -0.16% -0.18% -0.73% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 26 030 M - -
Net income 2021 6 696 M - -
Net Debt 2021 21 359 M - -
P/E ratio 2021 21,0x
Yield 2021 2,86%
Sales 2022 27 125 M - -
Net income 2022 7 877 M - -
Net Debt 2022 18 202 M - -
P/E ratio 2022 17,0x
Yield 2022 3,09%
Capitalization 139 B 139 B -
EV / Sales 2021 6,17x
EV / Sales 2022 5,81x
Nbr of Employees 24 300
Free-Float 99,8%
More Financials
Company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN... 
Sector
Pharmaceuticals
Calendar
08/03Earnings Release
More about the company
Ratings of Amgen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about AMGEN INC.
04:01pAMGEN : Announces Webcast Of 2021 Second Quarter Financial Results
PR
07/28AMGEN : Bradway Hails Industry Partnership Against COVID-19 at India Business Co..
PU
07/27AMGEN : Hiking Into the Wild With Her Son and in Memory of Her Husband
PU
07/27AMGEN : To Acquire Privately Held Teneobio for $900 Million In Cash
MT
07/27Amgen to Buy Teneobio; Deal Includes $900 Million Upfront, Potential Mileston..
DJ
07/27AMGEN : Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Includi..
PU
07/27AMGEN INC : Entry into a Material Definitive Agreement, Regulation FD Disclosure..
AQ
07/27AMGEN : To Acquire Privately Held Teneobio For $900 Million In Cash With Future ..
PR
07/27Amgen Inc. announced an agreement to acquire TeneoBio, Inc. for $2.5 billion.
CI
07/26AMGEN : Earns Place on Two ‘Best' Lists from Forbes
PU
07/22MARKET CHATTER : Amgen-Backed Singapore Biotech Hummingbird Considering US IPO
MT
07/22AMGEN : CEO Offers Career Advice to Summer Interns (And the Rest of Us)
PU
07/16AMGEN : Morgan Stanley Adjusts Price Target on Amgen to $280 From $278, Maintain..
MT
07/14AMGEN : Unites With Patient Organizations to Support Global Psoriatic Disease Co..
PU
07/14AMGEN : And The International Federation of Psoriasis Associations Launch UPLIFT..
PR
More news
News in other languages on AMGEN INC.
07/08Aktien New York Schluss: Corona-Sorgen belasten die Wall Street
07/08ASTRAZENECA : la FDA accorde une licence BLA au tezepelumab
07/08AMGEN : La FDA concede el procedimiento de evaluación rápida al fármaco de AZ-Am..
07/08FDA prüft Asthma-Mittel von Astrazeneca bevorzugt
07/01ETHICA GROUP : doppia operazione per Specchiasol
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | AMGN | US0311621009 | MarketScreener
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 242,46 $
Average target price 249,87 $
Spread / Average Target 3,06%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Executive Vice President-Research & Development
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.6.23%140 335
JOHNSON & JOHNSON9.40%453 418
ROCHE HOLDING AG12.49%332 374
PFIZER, INC.18.04%243 220
ELI LILLY AND COMPANY46.00%224 084
NOVARTIS AG0.39%223 750